Answers are grounded in this paper and cite their sources.
Characterizes outcomes of next-line therapies in low grade glioma, suggesting therapy options post-ivosidenib failure.
To characterize the outcomes of patients with low grade gliomas who undergo next-line therapies following disease progression after IDH inhibition
No takes yet. Share an insight, caveat, or question.
Minor et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: